We’re taking aim at chronic disease and we won’t give up until we conquer.
Biospherics is a leader in the application of
combination drugs to complex diseases, molecular
simulations and modeling, and research in the
metabolic syndrome. The Company’s newest lead
candidates are BSN908 for treatment of abdominal
aortic aneurysm, and BSN272, for reducing
triglycerides, cholesterol and
atherosclerosis. Biospherics also has phase 3
clinical trial results with BSN175, being developed
as an oral treatment for glycemic control in
patients with metabolic syndrome and diabetes.
For more on treatment of these diseases, see the pipeline.